Insufficient scRNA-seq data for expression of MRGBP at single-cell level.
Insufficient scRNA-seq data for expression of MRGBP at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
bladder | 100% | 972.81 | 21 / 21 | 100% | 41.38 | 504 / 504 |
ovary | 100% | 1357.75 | 180 / 180 | 100% | 29.82 | 430 / 430 |
skin | 100% | 1169.01 | 1809 / 1809 | 100% | 36.26 | 472 / 472 |
stomach | 100% | 799.58 | 359 / 359 | 100% | 40.55 | 286 / 286 |
uterus | 100% | 1018.08 | 170 / 170 | 100% | 43.87 | 459 / 459 |
breast | 100% | 964.22 | 459 / 459 | 100% | 30.89 | 1116 / 1118 |
lung | 100% | 969.87 | 577 / 578 | 100% | 36.19 | 1154 / 1155 |
brain | 100% | 767.00 | 2635 / 2642 | 100% | 21.74 | 705 / 705 |
thymus | 100% | 1056.19 | 653 / 653 | 100% | 24.35 | 603 / 605 |
intestine | 100% | 1134.41 | 966 / 966 | 100% | 47.19 | 525 / 527 |
kidney | 100% | 960.07 | 89 / 89 | 100% | 20.81 | 897 / 901 |
liver | 100% | 858.47 | 226 / 226 | 100% | 20.80 | 404 / 406 |
esophagus | 100% | 950.54 | 1445 / 1445 | 99% | 27.61 | 182 / 183 |
prostate | 100% | 1001.54 | 245 / 245 | 99% | 18.19 | 498 / 502 |
pancreas | 100% | 501.58 | 327 / 328 | 99% | 30.60 | 177 / 178 |
adrenal gland | 100% | 940.71 | 258 / 258 | 99% | 19.00 | 227 / 230 |
adipose | 100% | 943.25 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 31.95 | 29 / 29 |
spleen | 100% | 1293.65 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 34.65 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 23.26 | 1 / 1 |
muscle | 100% | 694.97 | 802 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 742.08 | 1333 / 1335 | 0% | 0 | 0 / 0 |
heart | 100% | 748.79 | 859 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 904.49 | 916 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 96% | 17.45 | 77 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006325 | Biological process | chromatin organization |
GO_0042981 | Biological process | regulation of apoptotic process |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_2000779 | Biological process | regulation of double-strand break repair |
GO_0051726 | Biological process | regulation of cell cycle |
GO_1905168 | Biological process | positive regulation of double-strand break repair via homologous recombination |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0005654 | Cellular component | nucleoplasm |
GO_0000786 | Cellular component | nucleosome |
GO_0035267 | Cellular component | NuA4 histone acetyltransferase complex |
GO_0005515 | Molecular function | protein binding |
Gene name | MRGBP |
Protein name | MRG/MORF4L-binding protein (MRG-binding protein) (Up-regulated in colon cancer 4) (Urcc4) |
Synonyms | C20orf20 |
Description | FUNCTION: Component of the NuA4 histone acetyltransferase (HAT) complex which is involved in transcriptional activation of select genes principally by acetylation of nucleosomal histones H4 and H2A. This modification may both alter nucleosome - DNA interactions and promote interaction of the modified histones with other proteins which positively regulate transcription. This complex may be required for the activation of transcriptional programs associated with oncogene and proto-oncogene mediated growth induction, tumor suppressor mediated growth arrest and replicative senescence, apoptosis, and DNA repair. NuA4 may also play a direct role in DNA repair when recruited to sites of DNA damage. |
Accessions | Q9NV56 ENST00000370487.5 |